Vimarsana
Biggest News Aggregation in the World

Page 13 - Cameron Durrant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cameron Durrant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cameron Durrant Today - Breaking & Trending Today

Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update - Vimarsana News

Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

Press release content from Business Wire. The AP news staff was not involved in its creation. Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update March 10, 2021 GMT BURLINGAME, Calif.--(BUSINESS WIRE)--Mar 10, 2021-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today reported financial results for the year ending December 31, 2020 and announced objectives for 2021. “...

Source: apnews.com
Pioneering General Counsel Mary Ann Hynes to host a candid Vanguard Network discussion on "My 3 Biggest Mistakes That Have Made Me a Better Leader" - Vimarsana News

Pioneering General Counsel Mary Ann Hynes to host a candid Vanguard Network discussion on "My 3 Biggest Mistakes That Have Made Me a Better Leader"

Pioneering General Counsel Mary Ann Hynes to host a candid Vanguard Network discussion on “My 3 Biggest Mistakes That Have Made Me a Better Leader” Share Article Sometimes the greatest learnings come the hard way. Longtime GC Mary Ann Hynes shares hers in an intimate, candid, confidential conversation with other leaders. "This is a rare opportunity to hear candid leadership lessons from one of the most experienced chief legal officers in the Fortune 500 world," said Ken Banta. NEW YORK (PRWEB) March 08, 2021 The Vanguard Net...

Source: prweb.com
Head of NYU Langone's Naik Lab, Shruti Naik, to be Session Leader at Upcoming Vanguard Network Forum - Vimarsana News

Head of NYU Langone's Naik Lab, Shruti Naik, to be Session Leader at Upcoming Vanguard Network Forum

Head of NYU Langone's Naik Lab, Shruti Naik, to be Session Leader at Upcoming Vanguard Network Forum Share Article Life Sciences experts will discuss the critical topic of population health as a competitive advantage at the next Vanguard Network forum for Life Sciences leaders NEW YORK (PRWEB) February 18, 2021 The Vanguard Network, which uniquely supports C-suite members in building their leadership capabilities, today announced that Shruti Naik, head of the Naik Lab at NYU Langone (https://naiklab.com/) will be one of three se...

Source: prweb.com
Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study - Vimarsana News

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

(1) SAN DIEGO and BURLINGAME, California, Jan. 27, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, and Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab, today announced the companies will be expanding their manufacturing agreement for the fill finish supply of lenzilumab, which is one of the few Phase 3 treatment options in...

Humanigen gains BARDA access to produce lenzilumab - Vimarsana News

Humanigen gains BARDA access to produce lenzilumab

Humanigen has expanded CRADA with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense for lenzilumab.